AIM ImmunoTech Inc. (AMEX:AIM) is a biotechnology company focused on developing immune-based therapies for the treatment of various diseases. The company is known for its work in immunotherapy, which involves using the body's immune system to fight diseases. AIM competes with other biotech firms in the immunotherapy space, striving to bring innovative treatments to market.

On June 17, 2025, AIM executed a reverse stock split at a ratio of 100 for 1. This strategic move is designed to increase the per-share market price of AIM's common stock. As highlighted by GlobeNewswire, the reverse stock split took effect on June 12, 2025, and temporarily changed the company's ticker symbol on the OTC Pink to AIMID for 20 trading days.

The primary goal of this reverse stock split is to help AIM regain compliance with the NYSE American's Listing Qualifications. This decision was approved by the company's stockholders during a Special Meeting on April 30, 2025. They agreed to amend the Certificate of Incorporation to allow for a reverse stock split at a ratio of up to 1-for-100, as determined by the Board of Directors.

Following the reverse stock split, AIM's stock price experienced a significant increase. The stock, trading on the AMEX exchange, is currently priced at $10.15. The stock reached a low of $8.50 and a high of $10.15 today, marking its highest price for the year.

AIM's market capitalization stands at approximately $7.76 million. This financial metric represents the total market value of the company's outstanding shares. The reverse stock split and subsequent price increase aim to enhance AIM's market position and attract more investors.